Prevalence of EML4-ALK Fusion Gene in Adenocarcinoma Lung Patients by Using Immuno Histo Chemistry

被引：0
|
作者：
Talwar, V. [1 ]
机构：
[1] Rajiv Gandhi Canc Hosp & Inst, Med Oncol, Delhi, India
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 09期
关键词：
EML4-ALK Immuno histo chemistry;
D O I：
10.1016/j.jtho.2018.07.054
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P15
引用
收藏
页码：S167 / S167
页数：1
相关论文
共 50 条
  • [41] Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients
    Wang, Wen-Tao
    Li, Yin
    Ma, Jie
    Chen, Xiao-Bing
    Qin, Jian-Jun
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (09) : 3927 - 3932
  • [42] Recurrence of Lung Adenocarcinoma After an Interval of 15 Years Revealed by Demonstration of the Same Type of EML4-ALK Fusion Gene
    Tsukamoto, Yoshitane
    Kanamori, Kiyonobu
    Watanabe, Takahiro
    Mikami, Koji
    Ieki, Ryuji
    Nakano, Takashi
    Kajimoto, Kazuyoshi
    Hirota, Seiichi
    PATHOLOGY RESEARCH AND PRACTICE, 2014, 210 (12) : 1112 - 1116
  • [43] Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant
    To, Ka-Fai
    Tong, Joanna H. M.
    Yeung, King S. F.
    Lung, Raymond W. M.
    Law, Peggy P. Y.
    Chau, Shuk Ling
    Kang, Wei
    Tong, Carol Y. K.
    Chow, Chit
    Chan, Anthony W. H.
    Leung, Linda K. S.
    Mok, Tony S. K.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) : 883 - 891
  • [44] Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors
    Gong, Jay
    Gregg, Jeffrey P.
    Ma, Weijie
    Yoneda, Ken
    Moore, Elizabeth H.
    Daly, Megan E.
    Zhang, Yanhong
    Williams, Melissa J.
    Li, Tianhong
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (04): : 297 - 301
  • [45] Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib
    Luo, Jing
    Gu, Dejian
    Lu, Huasong
    Liu, Si
    Kong, Jinliang
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : E266 - E268
  • [46] Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?
    Antoniu, Sabina Antonela
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (03) : 351 - 353
  • [47] A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib
    Zhong, Jiang-Ming
    Zhang, Gui-Feng
    Lin, Li
    Li, De-Yu
    Liu, Zhen-Hua
    LUNG CANCER, 2020, 145 : 211 - 212
  • [48] Non-small Cell Lung Cancer Patients with EML4-ALK Fusion Gene Are Insensitive to Cytotoxic Chemotherapy
    Morodomi, Yosuke
    Takenoyama, Mitsuhiro
    Inamasu, Eiko
    Toyozawa, Ryo
    Kojo, Miyako
    Toyokawa, Gouji
    Shiraishi, Yoshimasa
    Takenaka, Tomoyoshi
    Hirai, Fumihiko
    Yamaguchi, Masafumi
    Taguchi, Kenichi
    Seto, Takashi
    Sugio, Kenji
    Ichinose, Yukito
    ANTICANCER RESEARCH, 2014, 34 (07) : 3825 - 3830
  • [49] A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib A case report
    Guo, Jun
    Shi, Junping
    Yao, Ming
    Jin, Yi
    Liu, Dengxiang
    Liu, Weiling
    Wang, Kai
    Jiang, Da
    MEDICINE, 2020, 99 (45) : E22631
  • [50] Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene
    Kimura, Madoka
    Endo, Hiroko
    Inoue, Takako
    Nishino, Kazumi
    Uchida, Junji
    Kumagai, Toru
    Kukita, Yoji
    Kato, Kikuya
    Imamura, Fumio
    Inoue, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) : 527 - 530
12345